Overview

Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma

Status:
Recruiting

Trial end date:
2024-05-01

Target enrollment:

Participant gender:

Summary

This is a open-label, single center to determine the efficacy and safety of IM92 CAR-T cells in Patients With advanced gastric/esophagogastric combination adenocarcinoma that has failed at least second-line therapy and advanced pancreatic cancer that has failed at least first-line therapy.

Phase:

Early Phase 1

Details

Lead Sponsor:

Beijing Immunochina Medical Science & Technology Co., Ltd.